Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2022 Third Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2022 Second Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Year End Report applies the latest data to analyze current activities in the life sciences deal landscape.
How do you start an M&A discussion? Locust Walk has conducted an extensive study of mergers and acquisitions in biopharma completed in the past three years and uncovered an interesting trend leaders need to understand: the majority of acquirers only became...
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Q3 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life sciences deal...
In this report you can find an overview and analysis of the following across the iPSC market: Summary of iPS-derived cell therapy development landscape and key clinical trials IPO and private financing activity and performance Public market performance relative to...
